Comparison Ghrehlin at Obesity Without Metabolic Sydrome With Obesity with Metabolic Syndrome by Rusdiana et al.
ISSN Printed Version: 2549-4341  
ISSN Online Version: 2549-418X 
ABDIMAS TALENTA 6 (1) 2021: 174-178 http://abdimas.usu.ac.id 
Rusdiana et.al. Comparison Ghrehlin at Obesity Without Metabolic Sydrome 
174 
Comparison Ghrehlin at Obesity Without Metabolic Sydrome With 
Obesity with Metabolic Syndrome 
Rusdiana1*, Maya Savira2, Sry Suryani Widjaja1 
1Departement of Biochemistry, Faculty of Medical Universitas of Sumatera Utara 
2Departement of Physiology, Faculty of Medical Universitas of Sumatera Utara  
*Email: rusdiana@usu.ac.id
Abstract 
Obesity is principal causative factor in the development of metabolic syndrome and Ghrelin as human natural 
hormones is involved in fundamental regulatory processof eating and energy balance. Obesity, which has become 
a global public health problem, is one of the major risk factors for development metabolic syndrome and type 2 
diabetes mellitus.This study aimed to analyze the comparison of ghrelin hormone levels in obese with metabolic 
syndrome and obese non metabolic syndrome . The sample population is obese adults, then we examined the 
weight, height, waist size, blood pressure, laboratory tests such as blood sugar levels and lipid profile of sample 
population to separate obese with metabolic syndrome and obese non metabolic syndrome. After we determined 
each group we measured stress oxidative levels in blood in obese with metabolic syndrome and obese non 
metabolic syndrome by ELISA method.With statistical analysis using T test found that there was significant 
difference of ghrelin hormone levels between obese with metabolic syndrome and obese without metabolic 
syndrome (p<0.005). 
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1. INTRODUCTION
The incidence of obesity increase rapidly as a result of inactive lifestyle. The energy thst used for 
daily activity decrease parallels along with advances in technology. Based on WHO data there are 
1.6 billion adultswith overweight and 400 nmillion among them are obese (World Health 
Organization, 2015). Based on research data Riset Kesehatan Dasar in 2007 (Riskesdas, 2013), 
obesity prevalence in Indonesia generally in the population aged ≥ 15 years old is 10.3% (men 13.9% 
and women 23.8%)(Departemen Kesehatan  RI, 2009). An individu determined as obese based on 
Body Mass Index (BMI) it is a simple index of weight–height relationship calculated as weight in 
(kg) divided by height in (m) squared. One is categorized as obese I when the BMI 25-29,9 and 
obese II when the BMI BMI >30.  Metabolic syndrome is acondition that characterized by 
visceralobesity, increasing trygliceride levels and glucose and decreasing High Density Lipoprotein 
(HDL) and hypertension that can cause a greater risk incidence of type 2 DM and cardiovascular 
deseases (World Health Organization, 2000; Stern M et.al, 2004). Prevalences of metabolic 
syndrome varies greatly it is caused by uniformity criterias that used to determine, ethnic difference, 
sex and age. It can be confirmed that metabolic syndrome likely to increase parallels with obesity or 
central obesity prevalences (Sargowo D et.al, 2011; Carr DB et.al, 2004; Pusparini, 2007). 
Ghrelin is a peptide hormone from stomach with growth hormone releasing activity. It is also 
able to modify glucose and insulin metabolism, blood pressure levels,abiogenesis, and inflammatory 
processes in experimental conditions.  
Ghrelin is a peptide hormone comparising 28 amino acids from a 94 long amino acid precursor 
proghrelin. It is an orexigenic hormone. It is produced by x/A cells of oxyntic glands present in the 
mucosal layer of the fundus region odf stomach. A great deal of evidence suggests that ghrelin is 
involved in development of metabolic syndrome and type 2 diabetes mellitus. Ghrelin plays also 
important role in cardiovascular system. The recent literature suggests that in addition to food intake 
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and energy balance, ghrelin also controls glucose metabolism.Furthermore, current evidence 
suggests that ghrelin could contribute to the metabolic syndrome. It has been shown that ghrelin 
concentrations are reduced in different pathofisiological conditions including obesity, type 2diabetes 
and other conditions with metabolic disturbances. Low ghrelin concentrations are also associated 
with higher prevalence of the metabolic syndrome with progressively lower ghrelin levels in relation 
to the number of components of the metabolic syndrome (O.Ukkola et.al, 2009; .S.M.Poykko et.al, 
2010). It has been shown that ghrelin concentrations are reduced in different pathophysiological 
conditions including obesity, type 2 diabetes, and other conditions with metabolic disturbances (.R. 
Barazzoni et.al, 2007).  Ghrelin regulates homeostatic food intake, hedonic eating, and is a mediator 
in the stress response. Total plasma ghrelin and its associations with food intake, hedonic eating, and 
stress are decreased in obesity, providing evidence consistent with the theory that central resistance 
to ghrelin develops in obesity and ghrelin's function in appetite regulation may have evolved to 
prevent starvation in food scarcity rather than cope with modern food excess. Furthermore, ghrelin 
is associated with metabolic and cardiovascular health, and may have anti-aging effects, but these 
effects may be attenuated in obesity (Buss J et.al, 2014). Ghrelin is the only known circulating 
orexigenic factor, and has been found to be reduced in obese humans (Alvarez-Castro P et.al, 2013).  
The aim of this study to analyze the comparison ghrelin hormone level at obesity with metabolic 
syndrome and obesity without metabolic syndrome. 
 
2. MATERIAL AND METHODS 
This study involved 40 obesity subjects, all of whom were in good health. All subjects gave informed 
consent. This research was approved by Health Research Ethical Committee, Medical Faculty of 
Sumatera Utara/HAM General Hospital by Number 595/TGL/KEPK FK USU-RSUP HAM /2016. 
The inclusion criteria were the obesity people without medical history of diabetes or malignant 
disease. Subjects devided two groups, one group was obesity with metabolic syndrome and other 
group was obesity without metabolic syndrome. Each group consisted of 20 subjects.To determine 
whether the subject of the metabolic syndrome so examination of weight, height, waist size, blood 
pressure, laboratory tests such as blood sugar levels and lipid profile. Average age samples of obesity 
with metabolic syndrome 43.9±11.3 years and average age sample of obesity non metabolic 




All the samples we examined ghrelin hormone level in the serum by ELISA method. Collect plasm 
with EDTA-Na2 as anticoagulant. Centrifuge samples for 15 minutes at 1000xg at 2-80C within 30 
minutes of collection.Collect the supernatant and carry out the assay immediately. Dilute plasm 1:10, 
dilute 30 ml of concentrated wash buffer into 750 mL of wash Buffer with deionized or distilled 
water. Put unused solution back at 40C. If crystals have formed in the concentrate, we can warm it 
with 400C water bath.Incubate for 45 minutes at 370C, aspirate and wash 3 times, add 100 µL SABC 
(Streptavidin Conjugate) working solution into each well.Incubate 30 minutes at 370C aspirate and 
wash 5 times, add 90 µL TMB, incubate 15-20 minute at 370 C and then add 50µL stop solution and 




Statisical analysis was done using Microstat Statistical programme on an IBM compatible computer. 
T-tes was use compare T test found that there was significant difference of ghrelin hormone levels 
between obese with metabolic syndrome and obese without metabolic syndrome (p<0.005). 
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3. RESULT AND DISCUSSION 
 
The characteristics of the subjects of this research are shown in Table 3.1. Subjects in this research 
were not 20 years old. Body Mass Index (BMI) in the samples used in both obesity with metabolic 
syndrome and obesity non metabolic syndrome is >27, in this research the waist size of the samples 
at the obesity with metabolic syndrome found from 89- 119 cm and waist size of the obesity non 
metabolic syndrome found 97- 117 cm. Fasting Blood Gucose (FBG) in the obesity non metabolic 
syndrome samples were normal but the obesity with metabolic syndrome range from low to the 
moderately elevated range. Profile lipid like HDL value of the samples of obesity with metabolic 
syndrome range 34-60 mg/dL and HDL value of the samples of obesity non metabolic syndrome 
range 46-162 mg/dL. Trigliseride value of the samples of obesity with metabolic syndrome range 
91-452 mg/dL and obesity non metabolic syndrome was 46-162mg/dL. Dividing sample group in to 
obesity with metabolic syndrome and obesity non metabolic syndrome base on 3 criteria from 5 
criteria, that are  WS >102 cm at male and >88 at female, trigliseride levels ≥ 150mg/dL, HDL < 
40mg/dL at male and <50 mg/dL at female, Blood Pressure (BP) ≥130/85 Hg, so can be categorized 
as obesity with metabolic syndrome or obesity non metabolic syndrome. The result of measuring 
ghrelin hormone was found the lower value at obesity with metabolic syndrome was 414,56 pg/ml 
and the highest value at obesity with metabolic syndrome was 709,14 pg/ml and the lower value at 
obesity non metabolic syndrome was 801,20 pg/ml and the highest was 1335,9 pg/ml. 
 
  Obesity with 
metabolic syndrome 
Obesity non metabolic 
syndrome 
Age 43.9±11.3 34.55±10.8             
BMI 33.86±5.0 31.75±4.0                    
Waist size                                           107±10 104±15                                         
FBG                          101.85± 50.8 88.49±7.2           
HDL 63.2±23.85 46.05 ±6.99      
Trig 193.15±88.59 91.9±32.81               
Sistole                139.85 ± 16.3 123 ± 155              





Table 3.1. Baseline characteristic of the 40 samples 
 
This study aimed to analyze the ghrelin hormone levels in obese with metabolic syndrome 
and obese non metabolic syndrome,so we used the statistical analysis with T test found that there 
was significant difference of ghrelin hormone levels between obese with metabolic syndrome and 
obese without metabolic syndrome (p<0.005).This study ghrelin hormone value was highest at 
obesity without metabolic syndrome and the lower value we found at  obesity with metabolic 
syndrome . Like the preview study that low plasma ghrelin levels are associated with elevated fasting 
insulin levels and insulin resistance, suggesting both physiological and pathophysiological roles for 
ghrelin. For this reason, at least theoretically, ghrelin and/or its signalling manipulation could be 
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useful for the treatment or prevention of diseases of glucose homeostasis such as type 2 diabetes 
(Sangiao-Alvarellos S et.al, 2010). 
Current evidence suggests that ghrelin could contribute to the metabolic syndrome (M. 
Tsch¨op et.al, 2001; Tomomi Shiiya et.al, 2002). It has been shown that ghrelin concentrations are 
reduced in different pathophysiological conditions including obesity, type 2 diabetes, and other 
conditions with metabolic disturbances. Research by Matthias Tschop et al showed that plasma 
ghrelin concentration has been shown to be lowerin obese Caucasians when compared with lean 
Caucasians, like research by Tomomi Shiiya et al showed that plasma ghrelin concentration were 
higher in patients with anorexia nervosa and lower in patients with simple obesity compared with 
normal –weight control subjects. In my research was not done in lean samples but just at obesity 
with metabolic syndrome and obesity without metabolic syndrome, and we found that the obesity 
with metabolic syndrome was lower ghrelin levels than obesity without metabolic syndrome. As we 
know that Current evidence suggests that ghrelin could contribute to the metabolic syndrome. It has 
been shown that ghrelin concentrations are reduced in different pathophysiological conditions 
including obesity, type 2 diabetes, and other conditions with metabolic disturbances. Circulating 




The result this study shows that there was significant difference of ghrelin hormone levels between 
obese with metabolic syndrome and obese without metabolic syndrome (p<0.005). 
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